Please enable JavaScript to continue using this application.

Compare $SRPT vs $ZBIO | Chartloom

Compare

$SRPT vs $ZBIO

Sarepta Therapeutics Inc · Zenas Biopharma Inc

SRPT

Sarepta Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Compare $SRPT vs $ZBIO

Comparing Sarepta Therapeutics Inc and Zenas Biopharma Inc

SRPTSarepta Therapeutics Inc

ZBIOZenas Biopharma Inc

SRPTSarepta Therapeutics Inc

Market cap

$1.88B

P/E (TTM)

—

Forward P/E (NTM)

46.80x

Forward P/S (NTM)

1.31x

Rev growth (TTM)

-20.4%

YTD performance

-16.2%

52W performance

-23.7%

FCF yield

4.0%

ZBIOZenas Biopharma Inc

Market cap

$1.72B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-93.3%

YTD performance

-21.0%

52W performance

5.3%

FCF yield

-16.9%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

SRPT

ZBIO

Detailed metrics comparison

SRPT

Sarepta Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Market Cap

SRPT$1.88B

ZBIO$1.72B

Enterprise Value

SRPT$2.16B

ZBIO$1.91B

Price

SRPT$17.85

ZBIO$27.26

P/E Ratio

SRPTN/A

ZBION/A

P/S Ratio

SRPT0.95x

ZBIO1,720.92x

EV/Sales

SRPT1.09x

ZBIO1,913.10x

EV/EBITDA

SRPT12.13x

ZBIO0.00x

P/B Ratio

SRPT1.21x

ZBIO7.47x

P/FCF Ratio

SRPT25.00x

ZBION/A

EV/FCF

SRPT28.66x

ZBIO-6.57x

PEG Ratio

SRPTN/A

ZBION/A

Forward P/E (NTM)

SRPT46.80x

ZBION/A

Forward P/S (NTM)

SRPT1.31x

ZBION/A

Revenue (TTM)

SRPT$1.97B

ZBIO$1M

Revenue Growth (YoY)

SRPT-20.4%

ZBIO-93.3%

Forward Rev Growth

SRPT-23.2%

ZBIO5296.9%

Gross Margin (TTM)

SRPT67.5%

ZBIO0.0%

Operating Margin (TTM)

SRPT0.0%

ZBIO0.0%

EBITDA Margin (TTM)

SRPT7.5%

ZBIO-27387.0%

Net Margin (TTM)

SRPT-6.9%

ZBIO-48438.4%

FCF Margin (TTM)

SRPT3.8%

ZBIO-29097.4%

Net Income (TTM)

SRPT$-137M

ZBIO$-484M

FCF (TTM)

SRPT$75M

ZBIO$-291M

EPS (TTM)

SRPT-$1.30

ZBIO-$7.67

ROE (TTM)

SRPT-996.0%

ZBIO-18968.0%

ROA (TTM)

SRPT-414.0%

ZBIO-8991.0%

ROIC (TTM)

SRPT-605.0%

ZBIO-10131.0%

Cash

SRPT$571M

ZBIO$197M

Debt

SRPT$848M

ZBIO$389M

Net Cash/Debt

SRPT$-276M

ZBIO$-192M

Current Ratio (TTM)

SRPT4.42x

ZBIO9.93x

Quick Ratio (TTM)

SRPT2.57x

ZBIO9.77x

Debt/Equity (TTM)

SRPT0.55x

ZBIO1.57x

Debt/Assets (TTM)

SRPT0.0%

ZBIO0.0%

Interest Coverage (TTM)

SRPTN/A

ZBION/A

Net Debt/EBITDA (TTM)

SRPT0.00x

ZBIO0.00x

Beta

SRPT0.46

ZBIO0.70

52W Performance

SRPT-23.7%

ZBIO5.3%

YTD Performance

SRPT-16.2%

ZBIO-21.0%

% from 52W High

SRPT-27.7%

ZBIO-38.9%

% from 52W Low

SRPT21.6%

ZBIO101.9%

Asset Turnover (TTM)

SRPT0.60x

ZBIO0.00x

FCF Yield (TTM)

SRPT4.0%

ZBIO-16.9%

Earnings Yield (TTM)

SRPT-7.3%

ZBIO-28.1%

Dividend Yield (TTM)

SRPTN/A

ZBION/A

Rule of 40

SRPT-16.6

ZBIO-29,190.7

EV/GP/RG

SRPTN/A

ZBION/A

Ticker research

View SRPT research View ZBIO research

Metric	SRPT Sarepta Therapeutics Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$1.88B	$1.72B
Enterprise Value	$2.16B	$1.91B
Price	$17.85	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	0.95x	1,720.92x
EV/Sales	1.09x	1,913.10x
EV/EBITDA	12.13x	0.00x
P/B Ratio	1.21x	7.47x
P/FCF Ratio	25.00x	N/A
EV/FCF	28.66x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	46.80x	N/A
Forward P/S (NTM)	1.31x	N/A
Revenue & Growth
Revenue (TTM)	$1.97B	$1M
Revenue Growth (YoY)	-20.4%	-93.3%
Forward Rev Growth	-23.2%	5296.9%
Profitability
Gross Margin (TTM)	67.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	7.5%	-27387.0%
Net Margin (TTM)	-6.9%	-48438.4%
FCF Margin (TTM)	3.8%	-29097.4%
Net Income (TTM)	$-137M	$-484M
FCF (TTM)	$75M	$-291M
EPS (TTM)	-$1.30	-$7.67
ROE (TTM)	-996.0%	-18968.0%
ROA (TTM)	-414.0%	-8991.0%
ROIC (TTM)	-605.0%	-10131.0%
Financial Health
Cash	$571M	$197M
Debt	$848M	$389M
Net Cash/Debt	$-276M	$-192M
Current Ratio (TTM)	4.42x	9.93x
Quick Ratio (TTM)	2.57x	9.77x
Debt/Equity (TTM)	0.55x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.46	0.70
52W Performance	-23.7%	5.3%
YTD Performance	-16.2%	-21.0%
% from 52W High	-27.7%	-38.9%
% from 52W Low	21.6%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	4.0%	-16.9%
Earnings Yield (TTM)	-7.3%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-16.6	-29,190.7
EV/GP/RG	N/A	N/A
Ticker research	View SRPT research	View ZBIO research

Valuation

P/S Ratio

SRPT

0.95x

ZBIO

1,720.92x

EV/FCF

ZBIO

-6.57x

SRPT

28.66x

Growth & revenue

Revenue Growth TTM

SRPT

-20.4%

ZBIO

-93.3%

Forward Revenue Growth

ZBIO

5296.9%

SRPT

-23.2%

Profitability & performance

Gross Margin

SRPT

67.5%

ZBIO

0.0%

ROE

SRPT

-996.0%

ZBIO

-18968.0%

FCF Yield %

SRPT

4.0%

ZBIO

-16.9%

52-Week Performance

ZBIO

5.3%

SRPT

-23.7%

Detailed metrics comparison

SRPT

Sarepta Therapeutics Inc

ZBIO

Zenas Biopharma Inc

Market Cap

SRPT$1.88B

ZBIO$1.72B

Enterprise Value

SRPT$2.16B

ZBIO$1.91B

Price

SRPT$17.85

ZBIO$27.26

P/E Ratio

SRPTN/A

ZBION/A

P/S Ratio

SRPT0.95x

ZBIO1,720.92x

EV/Sales

SRPT1.09x

ZBIO1,913.10x

EV/EBITDA

SRPT12.13x

ZBIO0.00x

P/B Ratio

SRPT1.21x

ZBIO7.47x

P/FCF Ratio

SRPT25.00x

ZBION/A

EV/FCF

SRPT28.66x

ZBIO-6.57x

PEG Ratio

SRPTN/A

ZBION/A

Forward P/E (NTM)

SRPT46.80x

ZBION/A

Forward P/S (NTM)

SRPT1.31x

ZBION/A

Revenue (TTM)

SRPT$1.97B

ZBIO$1M

Revenue Growth (YoY)

SRPT-20.4%

ZBIO-93.3%

Forward Rev Growth

SRPT-23.2%

ZBIO5296.9%

Gross Margin (TTM)

SRPT67.5%

ZBIO0.0%

Operating Margin (TTM)

SRPT0.0%

ZBIO0.0%

EBITDA Margin (TTM)

SRPT7.5%

ZBIO-27387.0%

Net Margin (TTM)

SRPT-6.9%

ZBIO-48438.4%

FCF Margin (TTM)

SRPT3.8%

ZBIO-29097.4%

Net Income (TTM)

SRPT$-137M

ZBIO$-484M

FCF (TTM)

SRPT$75M

ZBIO$-291M

EPS (TTM)

SRPT-$1.30

ZBIO-$7.67

ROE (TTM)

SRPT-996.0%

ZBIO-18968.0%

ROA (TTM)

SRPT-414.0%

ZBIO-8991.0%

ROIC (TTM)

SRPT-605.0%

ZBIO-10131.0%

Cash

SRPT$571M

ZBIO$197M

Debt

SRPT$848M

ZBIO$389M

Net Cash/Debt

SRPT$-276M

ZBIO$-192M

Current Ratio (TTM)

SRPT4.42x

ZBIO9.93x

Quick Ratio (TTM)

SRPT2.57x

ZBIO9.77x

Debt/Equity (TTM)

SRPT0.55x

ZBIO1.57x

Debt/Assets (TTM)

SRPT0.0%

ZBIO0.0%

Interest Coverage (TTM)

SRPTN/A

ZBION/A

Net Debt/EBITDA (TTM)

SRPT0.00x

ZBIO0.00x

Beta

SRPT0.46

ZBIO0.70

52W Performance

SRPT-23.7%

ZBIO5.3%

YTD Performance

SRPT-16.2%

ZBIO-21.0%

% from 52W High

SRPT-27.7%

ZBIO-38.9%

% from 52W Low

SRPT21.6%

ZBIO101.9%

Asset Turnover (TTM)

SRPT0.60x

ZBIO0.00x

FCF Yield (TTM)

SRPT4.0%

ZBIO-16.9%

Earnings Yield (TTM)

SRPT-7.3%

ZBIO-28.1%

Dividend Yield (TTM)

SRPTN/A

ZBION/A

Rule of 40

SRPT-16.6

ZBIO-29,190.7

EV/GP/RG

SRPTN/A

ZBION/A

Ticker research

View SRPT research View ZBIO research

Metric	SRPT Sarepta Therapeutics Inc	ZBIO Zenas Biopharma Inc
Market & Valuation
Market Cap	$1.88B	$1.72B
Enterprise Value	$2.16B	$1.91B
Price	$17.85	$27.26
P/E Ratio	N/A	N/A
P/S Ratio	0.95x	1,720.92x
EV/Sales	1.09x	1,913.10x
EV/EBITDA	12.13x	0.00x
P/B Ratio	1.21x	7.47x
P/FCF Ratio	25.00x	N/A
EV/FCF	28.66x	-6.57x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	46.80x	N/A
Forward P/S (NTM)	1.31x	N/A
Revenue & Growth
Revenue (TTM)	$1.97B	$1M
Revenue Growth (YoY)	-20.4%	-93.3%
Forward Rev Growth	-23.2%	5296.9%
Profitability
Gross Margin (TTM)	67.5%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	7.5%	-27387.0%
Net Margin (TTM)	-6.9%	-48438.4%
FCF Margin (TTM)	3.8%	-29097.4%
Net Income (TTM)	$-137M	$-484M
FCF (TTM)	$75M	$-291M
EPS (TTM)	-$1.30	-$7.67
ROE (TTM)	-996.0%	-18968.0%
ROA (TTM)	-414.0%	-8991.0%
ROIC (TTM)	-605.0%	-10131.0%
Financial Health
Cash	$571M	$197M
Debt	$848M	$389M
Net Cash/Debt	$-276M	$-192M
Current Ratio (TTM)	4.42x	9.93x
Quick Ratio (TTM)	2.57x	9.77x
Debt/Equity (TTM)	0.55x	1.57x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.46	0.70
52W Performance	-23.7%	5.3%
YTD Performance	-16.2%	-21.0%
% from 52W High	-27.7%	-38.9%
% from 52W Low	21.6%	101.9%
Efficiency & Yields
Asset Turnover (TTM)	0.60x	0.00x
FCF Yield (TTM)	4.0%	-16.9%
Earnings Yield (TTM)	-7.3%	-28.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-16.6	-29,190.7
EV/GP/RG	N/A	N/A
Ticker research	View SRPT research	View ZBIO research